Market Place
Sourcing Support
China Adds LEQEMBI to National Drug Reimbursement List
08 Dec 2025 //
GLOBENEWSWIRE
Keytruda and Lenvima Show Long-Term Survival Benefit
18 Oct 2025 //
BUSINESSWIRE
TIME Selects Leqembi-Iqlik As Top Innovation Of 2025
14 Oct 2025 //
PR NEWSWIRE
First Patient Treated With Leqembi® (Lecanemab) In The Nordics
14 Oct 2025 //
PR NEWSWIRE
Eisai to Present 5-Year KEYNOTE-775 Data at ESMO 2025
02 Oct 2025 //
PR NEWSWIRE
FDA Begins sBLA for Leqembi® Iqlik as Early Alzheimer`s Treatment
02 Sep 2025 //
PR NEWSWIRE
Eisai Begins Rolling sBLA for Leqembi Iqlik in Early Alzheimer
02 Sep 2025 //
GLOBENEWSWIRE
FDA Approves Leqembi IQKLIK Injection for Early Alzheimer
30 Aug 2025 //
PR NEWSWIRE
Eisai Scores FDA Nod for Subcutaneous Leqembi Maintenance Dose
29 Aug 2025 //
FIERCE PHARMA
Leqembi® (lecanemab) launched in the EU today
25 Aug 2025 //
PR NEWSWIRE
Biogen’s Leqembi Advances as CEO Eyes Pipeline Rebuild
31 Jul 2025 //
BIOSPACE
Biogen, Eisai’s Leqembi Slows Alzheimer’s Over 4-Year Treatment
31 Jul 2025 //
BIOSPACE
Eisai to Share 4-Year Lecanemab Data at Alzheimer`s Conference
21 Jul 2025 //
PR NEWSWIRE
Lecanemab Drug Discovery Wins 9th Bioindustry Award in Japan
16 Jul 2025 //
PR NEWSWIRE
Eisai To Present E7386 At 2025 ASCO Annual Oncology Meeting
22 May 2025 //
PR NEWSWIRE
Eisai Forecasts Leqembi® Revenue at JPY 76.5 Billion in 2025
15 May 2025 //
PR NEWSWIRE
EU authorizes Eisai-Biogen`s drug for early Alzheimer`s treatment
16 Apr 2025 //
REUTERS
EU Commission refers lecanemab decision to Appeal Committee
01 Apr 2025 //
PR NEWSWIRE
Eisai`s abandoned Enhertu challenger set to live on at BlissBio
22 Mar 2025 //
FIERCE BIOTECH
Update On Regulatory Review Of Lecanemab In EU For Alzheimer`s
31 Jan 2025 //
PR NEWSWIRE
FDA OKs monthly maintenance dosing for Eisai/Biogen`s AD drug
27 Jan 2025 //
PRESS RELEASE
FDA Accepts LEQEMBI BLA for Subcutaneous Maintenance Dosing for AD
13 Jan 2025 //
PR NEWSWIRE
Leqembi® approved in Mexico
04 Dec 2024 //
PR NEWSWIRE
Leqembi (Lecanemab) Launched in South Korea for Alzheimer`s Disease
27 Nov 2024 //
PR NEWSWIRE
Leqembi® launched in South Korea
27 Nov 2024 //
PR NEWSWIRE
EU regulators endorse meds from BMS, J&J, Eisai and more
15 Nov 2024 //
FIERCE PHARMA
Eisai Upgrades Leqembi Sales Forecast To JPY 42.5 bn For Fis 2024
07 Nov 2024 //
PR NEWSWIRE
Eisai Completes BLA Submission for Leqembi® Subcutaneous Dosing
31 Oct 2024 //
PR NEWSWIRE
Eisai Presents Lecanemab Long-Term Data at CTAD Conference
30 Oct 2024 //
GLOBENEWSWIRE
Eisai Long-Term Lecanemab Data at 17th CTAD Conference
30 Oct 2024 //
PR NEWSWIRE
Eisai Presents Data on Inhibiting Tau Propagation with E2814
30 Oct 2024 //
PR NEWSWIRE
Eisai To Present Updated Lecanemab Data And Blood Biomarker At CTAD
23 Oct 2024 //
PR NEWSWIRE
Eisai To Request Reconsideration Of Lecanemab In Australia
16 Oct 2024 //
PR NEWSWIRE
Eisai To Present E7386 At ESMO Annual Meeting
08 Sep 2024 //
PR NEWSWIRE
Japan`s Eisai terminates ADC manufacturing pact with BMS
03 Jul 2024 //
BIOSPECTRUM ASIA
New Efficacy Data for Non-Clear Cell RCC a From KEYNOTE-B61 Added to LENVIMA
27 Jun 2024 //
PR NEWSWIRE
FDA Accepts Eisai’s Filing of LEQEMBI sBLA for IV for Early Alzheimer’s Disease
07 Jun 2024 //
GLOBENEWSWIRE
Eisai Initiates Leqembi Rolling BLA For Subcutaneous Maintenance Dosing
14 May 2024 //
PR NEWSWIRE
Eisai Initiates Leqembi Rolling BLA For Early Alzheimer`s Subcutaneous Dosing
14 May 2024 //
GLOBENEWSWIRE
BioArctic, Eisai Sign BAN2802 Research Evaluation Agreement
20 Apr 2024 //
PR NEWSWIRE
Submission of Leqembi® sBLA for the treatment of early AD to the FDA completed
31 Mar 2024 //
PR NEWSWIRE
LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME`s BEST INVENTIONS OF 2023
24 Oct 2023 //
PR NEWSWIRE
Eisai To Present Data From Leqembi® (Lecanemab-Irmb) Phase 3 Clarity Ad Study
15 Oct 2023 //
PR NEWSWIRE
LEQEMBI Lecanemab Approved for the Treatment of Alzheimer’s Disease in Japan
25 Sep 2023 //
GLOBENEWSWIRE
Merck and Eisai to stop Keytruda plus Lenvima trial in head and neck cancer
26 Aug 2023 //
ENDPTS
Eisai Files MAA For Lecanemab As Treatment For Early Alzheimer’S Disease
07 Jun 2023 //
PRESS RELEASE
Eisai Submits Maa For Lecanemab As Treatment For Early Alzheimer’S Disease
21 May 2023 //
PRESS RELEASE
Eisai inks Bliss ADC deal to challenge AstraZeneca blockbuster
09 May 2023 //
FIERCE BIOTECH
BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT
07 May 2023 //
PR NEWSWIRE
Eisai Publishes Long-Term Health Outcomes Using Simulation Model Of Lecanemab
03 Apr 2023 //
PR NEWSWIRE
Eisai Presented New Analyses of Aria and QOI On Lecanemab In Clarity Ad
30 Mar 2023 //
PR NEWSWIRE
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD
30 Mar 2023 //
GLOBENEWSWIRE
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab
30 Mar 2023 //
GLOBENEWSWIRE
A Total of 400 Million Yen Investment in Eisai for Neglected Tropical Diseases
29 Mar 2023 //
PR NEWSWIRE
Eisai publishes societal value of lecanemab using phase 3 Clarity AD data
19 Mar 2023 //
PR NEWSWIRE
FDA Accepts Eisai Filing of a Supplemental BLA of LEQEMBI
05 Mar 2023 //
GLOBENEWSWIRE
Eisai, Biogen say Alzheimer`s drug Lecanemab getting priority review in China
28 Feb 2023 //
REUTERS
Marketing Authorization for Lecanemab Accepted by EMA
26 Jan 2023 //
GLOBENEWSWIRE
Eisai Files MAA For Lecanemab For Alzheimer’S Disease In Japan
15 Jan 2023 //
PRESS RELEASE
BioArctic`s partner Eisai submits MAA for lecanemab for Alzheimer`s disease
10 Jan 2023 //
PR NEWSWIRE
